(328 days)
Not specified in the text.
Not Found
No
The description focuses on immunoassay and SPR technology, with no mention of AI or ML.
No
This device is an in vitro diagnostic assay used for the early detection and quantitative determination of pregnancy, not for treating or rehabilitating a disease or condition.
Yes.
The device is intended for the quantitative determination of human chorionic gonadotropin in EDTA-stabilized plasma, as an aid in the early detection of pregnancy, which is a diagnostic purpose.
No
The device description clearly outlines a hardware-based immunoassay using surface plasmon resonance (SPR) and antibodies, indicating it is not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states it's for the "quantitative determination of human chorionic gonadotropin in EDTA-stabilized plasma". This involves testing a sample taken from the body (plasma) in vitro (outside the body) to provide information about a physiological state (pregnancy).
- Device Description: The description details an "immunoassay" which is a common method used in IVD testing to detect and measure substances in biological samples.
- Performance Studies: The summary of performance studies includes analytical and clinical performance data, which are typical evaluations for IVD devices to demonstrate their accuracy and reliability in a clinical setting.
- Predicate Device: The mention of a "Predicate Device" (AxSYM® Total ß-hCG assay) is a strong indicator that this device is being compared to an existing IVD device for regulatory purposes.
All these elements align with the definition and characteristics of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
The Quantech Total β-hCG Assay is intended to be used, as aid in the early detection of pregnancy.
The Quantech Total β-hCG Assay is intended to be used for the quantitative determination of human chorionic gonadotropin in EDTA-stabilized plasma, for the early detection of pregnancy.
Product codes
NAL
Device Description
The Quantech Total ß-hCG assay is based on the principle of two site, or sandwich immunoassay in combination with surface plasmon resonance (SPR) surface mass measurement. Each test module contains a solid phase anti-ß-hCG monoclonal antibody immobilized onto a gold surface. An anti-hCG polyclonal antibody, used to enhance the specific detection by SPR is introduced sequentially.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Dilution Linearity/Parallelism - The parallelism study was conducted to evaluate the linearity of the Quantech Total ß-hCG Assay. Plasma samples were separately spiked with hCG and serially diluted with corresponding unspiked serum. The average percent of expected was 101%.
Recovery - Accuracy of the Quantech Total ß-hCG Assay was calculated from test results as the percentage of added analyte, corrected for endogenous analyte, recovered by the assay. After correcting for endogenous ß-hCG content, the average recovery was 104%.
Analytical Sensitivity - Multiple replicates of zero samples (male plasma) were assayed to determine the minimum quantity of ß-hCG detectable by the Quantech Assay. The average SPR signal shift plus two standard deviations (2 S.D.) was calculated and translated into a dose. The calculated analytical sensitivity of the Quantech Total β-hCG assay is 8.8 mlU/mL.
Precision - The INTRAASSAY precision was determined by evaluating three pools using 10 different biosensors in one day. The mean B-hCG concentrations (with % C. V.) were 38.7 (15.8%), 132 (12.8%), and 617 (4.5%) mlUmL for the low, medium and high pools, respectively.
The INTERASSAY precision was determined by evaluating three pools in triplicate on different days. The mean B-hCG concentrations (with % C.V.) were 41.3 (13.0%), 156 (11.4%), and 746 (7.0%) mIU/mL for the low, medium and high pools, respectively.
TOTAL IMPRECISION was determined from the interassay data, and is a combination of results from multiple runs on multiple days. The mean ß-hCG concentrations (with % C.V.) were 41.3 (18.5%), 156 (14.8%), and 746 (9.4%) mlU/mL for the low, medium and high pools, respectively.
Interfering Substances - Physiological interference was evaluated by spiking a plasma pool of hCG with hemoglobin, bilirubin and triglycerides at least ten times the highest expected physiological concentration. The percent recovery of β-hCG was determined to be acceptable in all three solutions based on the overlapping expected ranges before and affer spiking and no interference was noted by the endogenous substances in the Quantech Total 8-hCG Assay.
Hook Effect - Samples well beyond the standard curve range were assayed. No high dose hook effect was observed. Therefore, the Quantech Total B-hCG Assay does not give erroneously low results for greatly elevated samples up to at least 100,000 miU/mL.
Normal Range - Testing of apparently healthy, non-pregnant individuals demonstrated that the Quantech Total 3-hCG Assay and the predicate device perform similarly at and below the clinically accepted cut-off of 25 mlU/mL hCG. Both methods are also compatible with published expected values. The mean of the normals was below the detection limit of both assays.
The Quantech device demonstrates no false positive results with these apparently healthy individuals and is in 100% agreement with the predicate device.
Patient Sample Correlation - Results from human samples with values distributed throughout the quantitative range of the Quantech Total ß-hCG Assay, were compared with those obtained with a commercially available method (fluorogenic ELISA). The correlation coefficient was 0.98 (slope = 0.86, y-intercept = 7.2 mIU/mL).
Key Metrics
Analytical Sensitivity: 8.8 mlU/mL.
INTRAASSAY precision:
Low pool: 38.7 (15.8%) mlUmL
Medium pool: 132 (12.8%) mlUmL
High pool: 617 (4.5%) mlUmL
INTERASSAY precision:
Low pool: 41.3 (13.0%) mIU/mL
Medium pool: 156 (11.4%) mIU/mL
High pool: 746 (7.0%) mIU/mL
TOTAL IMPRECISION:
Low pool: 41.3 (18.5%) mlU/mL
Medium pool: 156 (14.8%) mlU/mL
High pool: 746 (9.4%) mlU/mL
Patient Sample Correlation: 0.98 (slope = 0.86, y-intercept = 7.2 mIU/mL).
Predicate Device(s)
AxSYM® Total ß-hCG assay
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1155 Human chorionic gonadotropin (HCG) test system.
(a)
Human chorionic gonadotropin (HCG) test system intended for the early detection of pregnancy —(1)Identification. A human chorionic gonadotropin (HCG) test system is a device intended for the early detection of pregnancy is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class II.(b)
Human chorionic gonadotropin (HCG) test system intended for any uses other than early detection of pregnancy —(1)Identification. A human chorionic goadotropin (HCG) test system is a device intended for any uses other than early detection of pregnancy (such as an aid in the diagnosis, prognosis, and management of treatment of persons with certain tumors or carcinomas) is intended to measure HCG, a placental hormone, in plasma or urine.(2)
Classification. Class III.(3)
Date PMA or notice of completion of a PDP is required. As of the enactment date of the amendments, May 28, 1976, an approval under section 515 of the act is required before the device described in paragraph (b)(1) may be commercially distributed. See § 862.3.
0
510(k) SUMMARY
Company Information
DEC 2 1 1998
Quantech Ltd. 1419 Energy Park Drive St. Paul. MN, 55108 (651) 647-6370 Thomas Witty, Ph.D. - Vice President, Research and Development
Contact Information
Robin J. Hellen, M.S. Hellen Professional Services (818) 709-5646
Product Name
| Classification Name: | Human Chorionic Gonadotropin (hCG) Test Systems, Class II |
|---|---|
| Trade Name: | Quantech Total β-hCG Assay |
| Common Name: | β-hCG Test Kit |
CLIA Categorization
We believe the Quantech Total ß-hCG Assay to be moderately categorized based on previous classification of analogous tests.
Substantial Equivalence
The Quantech Total ß-CG Assay is substantially equivalent to the AxSYM® Total ß-hCG assay marketed by Abbott Laboratories since 1998.
Intended Use
The Quantech Total β-hCG Assay is intended to be used, as aid in the early detection of pregnancy.
1
Device Description
The Quantech Total ß-hCG assay is based on the principle of two site, or sandwich immunoassay in combination with surface plasmon resonance (SPR) surface mass measurement. Each test module contains a solid phase anti-ß-hCG monoclonal antibody immobilized onto a gold surface. An anti-hCG polyclonal antibody, used to enhance the specific detection by SPR is introduced sequentially.
Comparison of Technological Characteristics
The Quantech Total ß-hCG Assay is similar to the AxSYM® Total ß-hCG assay as follows. Both assays are in vitro "sandwich" immunometric assays for the quantitative measurement of total ß-hCG. Additionally, both assays use antibody to ß-hCG coated on a solid support, and both instruments utilize a microprocessor for instrument control, data acquisition, and data reduction.
Summary of Non-Clinical Performance Data
Dilution Linearity/Parallelism - The parallelism study was conducted to evaluate the linearity of the Quantech Total ß-hCG Assay. Plasma samples were separately spiked with hCG and serially diluted with corresponding unspiked serum. The average percent of expected was 101%.
Recovery - Accuracy of the Quantech Total ß-hCG Assay was calculated from test results as the percentage of added analyte, corrected for endogenous analyte, recovered by the assay. After correcting for endogenous ß-hCG content, the average recovery was 104%.
Analytical Sensitivity - Multiple replicates of zero samples (male plasma) were assayed to determine the minimum quantity of ß-hCG detectable by the Quantech Assay. The average SPR signal shift plus two standard deviations (2 S.D.) was calculated and translated into a dose. The calculated analytical sensitivity of the Quantech Total β-hCG assay is 8.8 mlU/mL.
Precision - The INTRAASSAY precision was determined by evaluating three pools using 10 different biosensors in one day. The mean B-hCG concentrations (with % C. V.) were 38.7 (15.8%), 132 (12.8%), and 617 (4.5%) mlUmL for the low, medium and high pools, respectively.
The INTERASSAY precision was determined by evaluating three pools in triplicate on different days. The mean B-hCG concentrations (with % C.V.) were 41.3 (13.0%), 156 (11.4%), and 746 (7.0%) mIU/mL for the low, medium and high pools, respectively.
TOTAL IMPRECISION was determined from the interassay data, and is a combination of results from multiple runs on multiple days. The mean ß-hCG concentrations (with % C.V.) were 41.3 (18.5%), 156 (14.8%), and 746 (9.4%) mlU/mL for the low, medium and high pools, respectively.
2
Summary of Non-Clinical Performance Data (Cont.)
Interfering Substances - Physiological interference was evaluated by spiking a plasma pool of hCG with hemoglobin, bilirubin and triglycerides at least ten times the highest expected physiological concentration. The percent recovery of β-hCG was determined to be acceptable in all three solutions based on the overlapping expected ranges before and affer spiking and no interference was noted by the endogenous substances in the Quantech Total 8-hCG Assay.
Hook Effect - Samples well beyond the standard curve range were assayed. No high dose hook effect was observed. Therefore, the Quantech Total B-hCG Assay does not give erroneously low results for greatly elevated samples up to at least 100,000 miU/mL.
Summary of Clinical Performance Data
Normal Range - Testing of apparently healthy, non-pregnant individuals demonstrated that the Quantech Total 3-hCG Assay and the predicate device perform similarly at and below the clinically accepted cut-off of 25 mlU/mL hCG. Both methods are also compatible with published expected values. The mean of the normals was below the detection limit of both assays.
The Quantech device demonstrates no false positive results with these apparently healthy individuals and is in 100% agreement with the predicate device.
Patient Sample Correlation - Results from human samples with values distributed throughout the quantitative range of the Quantech Total ß-hCG Assay, were compared with those obtained with a commercially available method (fluorogenic ELISA). The correlation coefficient was 0.98 (slope = 0.86, y-intercept = 7.2 mIU/mL).
Conclusions Drawn From Performance Tests
The Quantech Total ß-hCG Assay provides results which are internally accurate, unaffected by ordinary variation of sample matrix and equivalent to the results obtained using the approved device in a valid laboratory setting.
Additionally, both clinically-based studies (normal range, patient correlation) demonstrated essential equivalence between the two devices as measured by their correlation and the dearee to which assay results are linearly related to one another over a broad range of values. Likewise, the normal range evaluation provided empirical evidence that the assay value is similar for both devices, and in agreement with published data.
3
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized caduceus symbol, which features a staff with a snake winding around it, and three horizontal bars above it. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the caduceus symbol.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
DEC 2 1 1999
BioCheck, Inc. c/o Ms. Robin J. Hellen, M.S. Hellen Professional Services 9418 Lasaine Avenue Northridge, California 91325
Re: K990258
Trade Name: Quantech Total ß-hCG Assay Regulatory Class: II Product Code: NAL Dated: November 18, 1999 Received: November 19, 1999
Dear Ms. Hellen:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic OS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
4
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Autman
Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
QUANTECH Total β-hCG ASSAY
Premarket Notification
RESPONSE A - Answers to FDA Questions
Statement for Indications for Use
| 510(k) Number (if known): | K990258 |
|---|---|
| Device Name: | Quantech Total β-hCG Assay |
Indications for Use:
The Quantech Total β-hCG Assay is intended to be used for the quantitative determination of human chorionic gonadotropin in EDTA-stabilized plasma, for the early detection of pregnancy.
Concurrence of the CDRH, Office of Device Evaluation (ODE)
| (Division Sign-Off) | Dean Cooper |
|---|---|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K990258 |
| Prescription Use: | OR | Over the Counter Use: |
|---|---|---|
1 12 2 2012 20:00 10